C07K 2319/72
Containing sh2 domain
Official title: containing SH2 domain
C07K2319/72 (Containing sh2 domain) appears on 22 US grants and 30 published applications in this corpus.
Search patents in C07K- Granted patents
- 22
- Published applications
- 30
- Assignees
- 18
- Inventors
- 66
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 4 |
| 2014 | 0 | 1 |
| 2015 | 3 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 3 |
| 2019 | 1 | 1 |
| 2020 | 1 | 3 |
| 2021 | 0 | 1 |
| 2022 | 2 | 3 |
| 2023 | 0 | 2 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric receptor comprising a ligand binding domain and an endodomain comprising a cytokine receptor endodomain and an intracellular T cell signalling domain12 May 2026US 12,624,088 B2Autolus Limited
- Anti-tumor fusion protein, preparation method therefor and application thereof24 Feb 2026US 12,558,403 B2Guangdong Taihe Medicine Science & Technology Co., Ltd
- Multispecific antibodies4 Jun 2024US 11,999,801 B2Hoffman-La Roche Inc.
- RNA engineered T cells for the treatment of cancer15 Mar 2022US 11,274,298 B2The Trustees of the University of Pennsylvania
- Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains8 Feb 2022US 11,242,377 B2Autolus Limited
- High affinity variants of sh2 domains26 Feb 2026US 2026/0055143 A1Axoiya Inc.
- Rna engineered t cells for the treatment of cancer6 Nov 2025US 2025/0340869 A1The Trustees of the University of Pennsylvania
- Pyk2-derived peptides for inhibiting invadopodia-mediated cancer metastasis7 Nov 2024US 2024/0368566 A1Bar-Ilan University
- Anti-tumor fusion protein, preparation method therefor and application thereof20 Jul 2023US 2023/0226157 A1Guangdong Taihe Medicine Science & Technology Co., Ltd
- Immune cells overexpressing cell signaling regulatory factor introduced from outside and use thereof6 Jul 2023US 2023/0212254 A1Beijing Yongtai Ruike Biotechnology Company Ltd
Most cited
By later US patents
- Totally synthetic affinity reagents69US 5,498,538 AThe University of North Carolina at Chapel Hill · 1996
- Random peptide library36US 5,747,334 AThe University of North Carolina at Chapel Hill · 1998
- Coiled-coil mediated heterodimerization functional interaction trap32US 6,790,624 B2University of Connecticut · 2004
- Totally Synthetic Affinity Reagents24US 5,948,635 AThe University of North Carolina at Chapel Hill · 1999
- Cell based assay for identifying sh2-domain-specific signal transducer antagonist12US 6,303,319 B1ARIAD Pharmaceuticals, Inc. · 2001